UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
| |||
(State or other jurisdiction of incorporation) |
| (Commission File Number) |
| (IRS Employer Identification No.) |
(Address of principal executive offices) (Zip Code)
(
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|
|
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
| Trading Symbol(s) |
| Name of each exchange on which registered |
|
| The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On November 2, 2021, Pacific Biosciences of California, Inc. (the “Company”) announced its financial results for its third fiscal quarter ended September 30, 2021. A copy of the press release containing the announcement is attached as Exhibit 99.1 hereto and is incorporated herein by reference.
This information, as well as Exhibit 99.1, is intended to be furnished under Item 2.02 of Form 8-K, “Results of Operations and Financial Condition” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
|
| |
(d) |
| Exhibits. |
|
|
|
99.1 |
| |
|
|
|
104 |
| Cover Page Interactive Data File (embedded within the Inline XBRL document) |
|
|
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
| Pacific Biosciences of California, Inc. | |
|
|
|
| By: | /s/ Michele Farmer |
|
| Michele Farmer |
|
| Vice President and Chief Accounting Officer |
Date: November 2, 2021 |
|
|
PacBio Announces Third Quarter 2021 Financial Results
Menlo Park, Calif. – November 2, 2021 – PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2021.
Record revenue reflects 6th straight quarter of sequential growth
|
· |
Revenue of $34.9 million, an 83% increase compared with $19.1 million in the prior year period. |
|
· |
Placed 44 Sequel II/IIe systems during the quarter compared to 20 Sequel II systems placed in the prior year quarter and 38 Sequel II/IIe systems placed in the second quarter of 2021. |
|
· |
Installed base of 326 Sequel II/IIe systems as of September 30, 2021, compared with 168 as of September 30, 2020. |
|
· |
Instrument revenue of $15.9 million, compared with $7.7 million in the prior year period. |
|
· |
Consumables revenue of $14.6 million compared with $8.0 million in the prior year period. |
|
· |
Service and other revenue of $4.4 million compared with $3.3 million in the prior year period. |
Gross profit for the third quarter of 2021 was $15.4 million, representing a 117% increase compared with $7.1 million for the third quarter of 2020 and gross margin of 44% in the period compared to 37% for the third quarter of 2020. Excluding merger-related fair value inventory adjustments and amortization of intangible assets, non-GAAP gross profit for the third quarter of 2021 was $15.7 million and represented a non-GAAP gross margin of 45% in the third quarter of 2021, compared to 37% for the third quarter of 2020.
Operating expenses totaled $89.8 million for the third quarter of 2021, compared to $31.2 million for the third quarter of 2020. Excluding merger-related expenses and amortization of intangible assets, non-GAAP operating expenses totaled $59.1 million for the third quarter of 2021, compared to $31.2 million for the third quarter of 2020. Operating expenses for the third quarter of 2021 and the third quarter of 2020 included non-cash stock-based compensation of $26.6 million and $4.3 million, respectively. Excluding merger-related expenses, operating expenses in the third quarter of 2021 included $15.1 million of non-cash stock-based compensation.
Net income for the third quarter of 2021 was $16.5 million, compared to a net loss of $23.7 million for the third quarter of 2020. Excluding merger-related expenses, an income tax benefit resulting from the acquisitions of Omniome and Circulomics, fair value inventory adjustments, and amortization of intangible assets, non-GAAP net loss for the third quarter of 2021 was $47.2 million, compared to $23.7 million for the third quarter of 2020.
Basic and diluted net income per share for the third quarter of 2021 was $0.08 compared to net loss per share of $0.14 for the third quarter of 2020. Non-GAAP net loss per share for the third quarter of 2021 was $0.23 compared to $0.14 for the third quarter of 2020.
Cash, cash equivalents and investments, excluding short and long-term restricted cash, at September 30, 2021, totaled $1,079.9 million, compared to $318.8 million at December 31, 2020.
Updates since our last earnings release
|
· |
Closed previously announced acquisition of Omniome, which adds a highly differentiated short-read sequencing technology capable of delivering increased sequencing accuracy and establishes a San Diego presence |
|
· |
Completed a $300 million PIPE financing in support of Omniome acquisition from a premier syndicate of life sciences investors |
|
· |
Partnered with the European Reference Genome Atlas (ERGA) consortium to support its efforts in understanding and protecting biodiversity by generating high-quality reference genomes for European plant and animal species |
|
· |
Announced Prenetics Group Limited, a leading global genomics and diagnostic testing company, will use PacBio HiFi sequencing for its comprehensive genetic screening services outside of the United States |
|
· |
Sequel II became PacBio’s first regulatory approved instrument as Berry Genomics announced it obtained China NMPA approval for the system and related reagents |
“Our focus on execution enabled us to achieve another record quarter, highlighted by Sequel II/IIe installations at an all-time high,” said Christian Henry, President and Chief Executive Officer. “We continue to build momentum, and we are just beginning to see the tangible results from our investments in the business. With approximately 700 global employees, an expanding commercial presence, and groundbreaking short- and long-read products in development, PacBio is in prime position to deliver on its mission to enable the promise of genomics to better human health.”
Impact of COVID-19 Pandemic
Financial results for the third quarter of 2020 were negatively impacted as multiple customers postponed system deliveries, and the financial results for much of 2020 were further impacted as several customers shut down or limited operations for various periods to help curb the spread of the COVID-19 pandemic. Instrument utilization largely returned to normal by the fourth quarter of 2020, and we subsequently have not seen significant issues with deliveries or operations at customer sites. This resulted in higher product revenues of $30.5 million for the third quarter of 2021 compared to $15.7 million for the same period of 2020. Uncertainties associated with the pandemic, including recent resurgences in infection rates, may cause further impacts to our operations and financial results.
Quarterly Conference Call Information
Management will host a quarterly conference call to discuss its third quarter ended September 30, 2021, results today at 4:30 p.m. Eastern Time. Investors may listen to the call by dialing 1.888.366.7247, or if outside the U.S., by dialing +1.707.287.9330, using Conference ID # 5129207. The call will be webcast live and will be available for replay at PacBio’s website at https://investor.pacificbiosciences.com/.
About PacBio
Pacific Biosciences of California, Inc. (NASDAQ: PACB), is empowering life scientists with highly accurate long-read sequencing. The company’s innovative instruments are based on Single Molecule, Real-Time (SMRT®) Sequencing technology, which delivers a comprehensive view of genomes, transcriptomes, and epigenomes, enabling access to the full spectrum of genetic variation in any organism. Cited in thousands of peer-reviewed publications, PacBio® sequencing systems are in use by scientists around the world to drive discovery in human biomedical research, plant and animal sciences, and microbiology.
Statement regarding use of non‐GAAP financial measures
The company reports non‐GAAP results for basic and diluted net income and loss per share, net income, net loss, gross margins, gross profit and operating expenses in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The company’s financial measures under GAAP include substantial charges such as merger related expenses, and others that are listed in the itemized reconciliations between GAAP and non‐GAAP financial measures included in this press release. The amortization of intangible assets excluded from GAAP financial measures relates to acquired intangible assets that were recorded as part of the purchase accounting this quarter. Such intangible assets contribute to revenue generation and its amortization will recur in future periods until they are fully amortized. Management has excluded the effects of these items in non‐GAAP measures to assist investors in analyzing and assessing past and future operating performance. In addition, management uses non-GAAP measures to compare our performance relative to forecasts and strategic plans and to benchmark our performance externally against competitors.
The company encourages investors to carefully consider its results under GAAP, as well as its supplemental non‐GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non‐GAAP results are presented in the tables of this release.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995, including statements relating to potential increased accuracy of short-read sequencing technology; collaboration efforts, including in connection with establishing reference genomes; potential use of PacBio products and technology by Prenetics Group Limited in its genetic screening products and services; and expectations regarding PacBio’s
momentum, potential expansion of commercial presence, capabilities and development of short- and long-read products and technology, position and ability to enable genomics and better human health, and business investments. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond PacBio’s control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in PacBio’s most recent filings with the Securities and Exchange Commission, including PacBio’s most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption “Risk Factors.” PacBio undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.
The condensed consolidated financial statements that follow should be read in conjunction with the notes set forth in PacBio’s Quarterly Report on Form 10-Q when filed with the Securities and Exchange Commission.
Contacts
Investors:
Todd Friedman
650.521.8450
ir@pacificbiosciences.com
Media:
Kathy Lynch
pr@pacificbiosciences.com
Pacific Biosciences of California, Inc.
Unaudited Condensed Consolidated Statement of Operations
(in thousands, except per share amounts)
|
|
Three Months Ended |
|||||||
|
|
September 30, 2021 |
June 30, 2021 |
September 30, 2020 |
|||||
|
Revenue: |
||||||||
|
Product revenue |
$ |
30,502 |
$ |
26,533 |
$ |
15,749 | ||
|
Service and other revenue |
4,385 | 4,077 | 3,333 | |||||
|
Total revenue |
34,887 | 30,610 | 19,082 | |||||
|
Cost of revenue: |
||||||||
|
Cost of product revenue |
15,530 | 13,222 | 9,228 | |||||
|
Cost of service and other revenue |
3,870 | 3,635 | 2,790 | |||||
|
Amortization of intangible assets |
123 |
— |
— |
|||||
|
Total cost of revenue |
19,523 | 16,857 | 12,018 | |||||
|
Gross profit |
15,364 | 13,753 | 7,064 | |||||
|
Operating expense: |
||||||||
|
Research and development |
27,508 | 22,266 | 16,467 | |||||
|
Sales, general and administrative |
31,606 | 29,060 | 14,772 | |||||
|
Merger-related expenses (1) |
30,726 |
— |
||||||
|
Total operating expense |
89,840 | 51,326 | 31,239 | |||||
|
|
||||||||
|
Operating loss |
(74,476) | (37,573) | (24,175) | |||||
|
Interest expense |
(3,673) | (3,589) |
— |
|||||
|
Other income (expense), net |
(133) | 161 | 467 | |||||
|
Loss before benefit from income taxes |
(78,282) | (41,001) | (23,708) | |||||
|
Benefit from income taxes (2) |
(94,824) |
— |
— |
|||||
|
Net income (loss) |
$ |
16,542 |
$ |
(41,001) |
$ |
(23,708) | ||
|
|
||||||||
|
Net income (loss) per share: |
||||||||
|
Basic |
$ |
0.08 |
$ |
(0.21) |
$ |
(0.14) | ||
|
Diluted |
$ |
0.08 |
$ |
(0.21) |
$ |
(0.14) | ||
|
|
||||||||
|
Shares used in computing net income (loss) per share: |
|
|
|
|
|
|
|
|
|
Basic |
202,194 | 198,568 | 166,862 | |||||
|
Diluted |
215,127 | 198,568 | 166,862 | |||||
__________
|
(1) |
Merger-related expenses for the three months ended September 30, 2021 consist of $11.8 million of transaction costs arising from the acquisitions of Omniome and Circulomics and $18.9 million of stock-based compensation expense resulting from the acceleration of certain equity awards in connection with the Omniome merger. |
|
(2) |
A deferred income tax benefit of $94.8 million for the three months ended September 30, 2021, is related to the release of the valuation allowance for deferred tax assets due to the recognition of deferred tax liabilities in connection with the Omniome and Circulomics acquisitions. |
Pacific Biosciences of California, Inc.
Unaudited Condensed Consolidated Statement of Operations
(in thousands, except per share amounts)
|
|
|||||||||||
|
|
Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||||
|
|
2021 |
2020 |
2021 |
2020 |
|||||||
|
Revenue: |
|||||||||||
|
Product revenue |
$ |
30,502 |
$ |
15,749 |
$ |
82,338 |
$ |
41,798 | |||
|
Service and other revenue |
4,385 | 3,333 | 12,156 | 9,959 | |||||||
|
Total revenue |
34,887 | 19,082 | 94,494 | 51,757 | |||||||
|
Cost of revenue: |
|||||||||||
|
Cost of product revenue |
15,530 | 9,228 | 41,449 | 22,874 | |||||||
|
Cost of service and other revenue |
3,870 | 2,790 | 10,828 | 7,718 | |||||||
|
Amortization of intangible assets |
123 |
— |
123 |
— |
|||||||
|
Total cost of revenue |
19,523 | 12,018 | 52,400 | 30,592 | |||||||
|
Gross profit |
15,364 | 7,064 | 42,094 | 21,165 | |||||||
|
Operating expense: |
|||||||||||
|
Research and development |
27,508 | 16,467 | 70,323 | 46,727 | |||||||
|
Sales, general and administrative |
31,606 | 14,772 | 86,804 | 54,846 | |||||||
|
Merger-related expenses (1) |
30,726 |
— |
30,726 |
— |
|||||||
|
Total operating expense |
89,840 | 31,239 | 187,853 | 101,573 | |||||||
|
|
|||||||||||
|
Operating loss |
(74,476) | (24,175) | (145,759) | (80,408) | |||||||
|
Gain (loss) from Continuation Advances from Illumina |
— |
— |
(52,000) | 34,000 | |||||||
|
Interest expense |
(3,673) |
— |
(9,051) | (267) | |||||||
|
Other income (expense), net |
(133) | 467 | 92 | 1,143 | |||||||
|
Loss before benefit from income taxes |
(78,282) | (23,708) | (206,718) | (45,532) | |||||||
|
Benefit from income taxes (2) |
(94,824) |
— |
(94,824) |
— |
|||||||
|
Net income (loss) |
$ |
16,542 |
$ |
(23,708) |
$ |
(111,894) |
$ |
(45,532) | |||
|
|
|||||||||||
|
Net income (loss) per share: |
|||||||||||
|
Basic |
$ |
0.08 |
$ |
(0.14) |
$ |
(0.56) |
$ |
(0.29) | |||
|
Diluted |
$ |
0.08 |
$ |
(0.14) |
$ |
(0.56) |
$ |
(0.29) | |||
|
|
|||||||||||
|
Shares used in computing net income (loss) per share: |
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
202,194 | 166,862 | 198,545 | 158,195 | |||||||
|
Diluted |
215,127 | 166,862 | 198,545 | 158,195 | |||||||
|
|
|||||||||||
__________
|
(1) |
Merger-related expenses for the three months and nine months ended September 30, 2021 consist of $11.8 million of transaction costs arising from the acquisitions of Omniome and Circulomics and $18.9 million of stock-based compensation expense resulting from the acceleration of certain equity awards in connection with the Omniome merger. |
|
(2) |
A deferred income tax benefit of $94.8 million for the three months and nine months ended September 30, 2021, is related to the release of the valuation allowance for deferred tax assets due to the recognition of deferred tax liabilities in connection with the Omniome and Circulomics acquisitions. |
Pacific Biosciences of California, Inc.
Unaudited Condensed Consolidated Balance Sheets
(in thousands)
|
|
|||||
|
|
September 30, |
December 31, |
|||
|
|
2021 |
2020 |
|||
|
Assets |
|||||
|
Cash and investments |
$ |
1,079,890 |
$ |
318,814 | |
|
Accounts receivable |
23,946 | 16,837 | |||
|
Inventory |
18,276 | 14,230 | |||
|
Prepaid and other current assets |
7,193 | 4,870 | |||
|
Property and equipment, net |
31,119 | 24,899 | |||
|
Operating lease right-of-use assets, net |
45,862 | 29,951 | |||
|
Restricted cash |
5,060 | 4,336 | |||
|
Intangible assets, net |
411,206 |
— |
|||
|
Goodwill |
411,533 |
— |
|||
|
Other long-term assets |
70 | 43 | |||
|
Total Assets |
$ |
2,034,155 |
$ |
413,980 | |
|
Liabilities and Stockholders' Equity |
|||||
|
Accounts payable |
$ |
4,960 |
$ |
3,579 | |
|
Accrued expenses |
30,820 | 17,350 | |||
|
Deferred revenue |
28,220 | 10,290 | |||
|
Operating lease liabilities |
57,082 | 41,999 | |||
|
Contingent consideration liability |
168,574 |
— |
|||
|
Convertible senior notes, net |
895,915 |
— |
|||
|
Other liabilities |
7,777 | 5,271 | |||
|
Stockholders' equity |
840,807 | 335,491 | |||
|
Total Liabilities and Stockholders' Equity |
$ |
2,034,155 |
$ |
413,980 | |
Pacific Biosciences of California, Inc.
Reconciliation of Non-GAAP Financial Measures
(in thousands, except per share amounts)
|
|
Three Months Ended |
Nine Months Ended |
||||||||||||
|
|
September 30, |
June 30, |
September 30, |
September 30, |
September 30, |
|||||||||
|
|
2021 |
2021 |
2020 |
2021 |
2020 |
|||||||||
|
|
||||||||||||||
|
GAAP net income (loss) |
$ |
16,542 |
$ |
(41,001) |
$ |
(23,708) |
$ |
(111,894) |
$ |
(45,532) | ||||
|
Merger-related expenses (1) |
30,726 |
— |
— |
30,726 |
— |
|||||||||
|
Income tax benefit resulting from acquisitions (2) |
(94,824) |
— |
— |
(94,824) |
— |
|||||||||
|
Fair value adjustment to Circulomics inventory at acquisition date |
|
183 |
|
|
— |
|
|
— |
|
|
183 |
|
|
|
|
Amortization of intangible assets |
154 |
— |
— |
154 |
— |
|||||||||
|
Loss (gain) from Continuation Advances from Illumina |
— |
— |
— |
52,000 | (34,000) | |||||||||
|
Non-GAAP net loss |
$ |
(47,219) |
$ |
(41,001) |
$ |
(23,708) |
$ |
(123,655) |
$ |
(79,532) | ||||
|
|
||||||||||||||
|
GAAP net income (loss) per share - diluted |
$ |
0.08 |
$ |
(0.21) |
$ |
(0.14) |
$ |
(0.56) |
$ |
(0.29) | ||||
|
Merger-related expenses (1) |
0.15 |
— |
— |
0.15 |
— |
|||||||||
|
Income tax benefit resulting from acquisitions (2) |
(0.47) |
— |
— |
(0.48) |
— |
|||||||||
|
Loss (gain) from Continuation Advances from Illumina |
— |
— |
— |
0.26 | (0.21) | |||||||||
|
Other adjustments and rounding differences |
0.01 |
— |
— |
0.01 |
— |
|||||||||
|
Non-GAAP net loss per share - diluted |
$ |
(0.23) |
$ |
(0.21) |
$ |
(0.14) |
$ |
(0.62) |
$ |
(0.50) | ||||
|
|
||||||||||||||
|
GAAP gross profit |
$ |
15,364 |
$ |
13,753 |
$ |
7,064 |
$ |
42,094 |
$ |
21,165 | ||||
|
Fair value adjustment to Circulomics inventory at acquisition date |
|
183 |
|
|
— |
|
|
— |
|
|
183 |
|
|
— |
|
Amortization of intangible assets |
123 |
— |
— |
123 |
— |
|||||||||
|
Non-GAAP gross profit |
$ |
15,670 |
$ |
13,753 |
$ |
7,064 |
$ |
42,400 |
$ |
21,165 | ||||
|
|
||||||||||||||
|
GAAP total operating expense |
$ |
89,840 |
$ |
51,326 |
$ |
31,239 |
$ |
187,853 |
$ |
101,573 | ||||
|
Merger-related expenses (1) |
(30,726) |
— |
— |
(30,726) |
— |
|||||||||
|
Amortization of intangible assets |
(31) |
— |
— |
(31) |
— |
|||||||||
|
Non-GAAP total operating expense |
$ |
59,083 |
$ |
51,326 |
$ |
31,239 |
$ |
157,096 |
$ |
101,573 | ||||
|
|
||||||||||||||
__________
|
(1) |
Merger-related expenses for the three months and nine months ended September 30, 2021 consist of $11.8 million of transaction costs arising from the acquisitions of Omniome and Circulomics and $18.9 million of stock-based compensation expense resulting from the acceleration of certain equity awards in connection with the Omniome merger. |
|
(2) |
A deferred income tax benefit of $94.8 million for the three months and nine months ended September 30, 2021, is related to the release of the valuation allowance for deferred tax assets due to the recognition of deferred tax liabilities in connection with the Omniome and Circulomics acquisitions. |